274 related articles for article (PubMed ID: 1920864)
1. [Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome].
Fukao H; Yamamoto K; Matsuo O
Rinsho Byori; 1991 Jul; 39(7):720-6. PubMed ID: 1920864
[TBL] [Abstract][Full Text] [Related]
2. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC].
Nagaizumi K; Kuroso K; Amano K; Sato T; Fukutake K; Fujimaki M
Rinsho Byori; 1994 Jul; 42(7):707-12. PubMed ID: 8065036
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor activity in bacterial infection.
Páramo JA; Fernández Diaz FJ; Rocha E
Thromb Haemost; 1988 Jun; 59(3):451-4. PubMed ID: 3142082
[TBL] [Abstract][Full Text] [Related]
4. [Tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI)].
Hayashi T
Rinsho Byori; 1994 Apr; 42(4):346-51. PubMed ID: 8176842
[TBL] [Abstract][Full Text] [Related]
5. Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation.
Fukao H; Ueshima S; Okada K; Yamamoto K; Matsuo T; Matsuo O
Thromb Res; 1992 Oct; 68(1):57-65. PubMed ID: 1280377
[TBL] [Abstract][Full Text] [Related]
6. [A new advance in theory of blood coagulation and fibrinolysis and its practical application].
Matsuno K; Araki K
Rinsho Byori; 1991 Feb; 39(2):179-84. PubMed ID: 1904112
[TBL] [Abstract][Full Text] [Related]
7. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
[TBL] [Abstract][Full Text] [Related]
8. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
9. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
10. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
11. Determinants of induction of increased synthesis of plasminogen activator inhibitor type-1 in human endothelial cells by t-PA.
Fujii S; Sobel BE
Thromb Haemost; 1992 Feb; 67(2):233-8. PubMed ID: 1621243
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
Pedersen OD; Gram J; Jespersen J
Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
[TBL] [Abstract][Full Text] [Related]
13. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
[TBL] [Abstract][Full Text] [Related]
14. A kinetic model of the circulatory regulation of tissue plasminogen activator.
Chandler WL
Thromb Haemost; 1991 Sep; 66(3):321-8. PubMed ID: 1746003
[TBL] [Abstract][Full Text] [Related]
15. Induction of synthesis of plasminogen activator inhibitor type-1 by tissue-type plasminogen activator in human hepatic and endothelial cells.
Fujii S; Lucore CL; Hopkins WE; Billadello JJ; Sobel BE
Thromb Haemost; 1990 Nov; 64(3):412-9. PubMed ID: 2128971
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy.
Estellés A; Gilabert J; Andrés C; España F; Aznar J
Thromb Haemost; 1990 Oct; 64(2):281-5. PubMed ID: 2125378
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
18. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
[TBL] [Abstract][Full Text] [Related]
19. [New useful parameters or makers in diagnosis and condition. Analysis of disseminated intravascular coagulation--mainly molecular markers].
Koike K; Fujimaki M
Nihon Rinsho; 1993 Jan; 51(1):37-42. PubMed ID: 8433526
[TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: clinicopathologic correlations.
Francis RB; Seyfert U
J Lab Clin Med; 1987 Nov; 110(5):541-7. PubMed ID: 3117952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
